Christopher Tehrani | کریستوفر تهرانی

Christopher Tehrani

Christopher is head of Schjødt’s cross-border IP practice and a Partner and a seasoned trial attorney with focus on IPR litigation and in particular regarding patents, trade secrets and trademarks. He frequently advises clients in a wide range of industries and his experience includes extensive work with numerous high value pan-European litigations relating to pharmaceuticals, telecom and medical devices. He also advises Life Sciences clients on regulatory issues. Furthermore, he regularly assists clients on issues relating to market law, drafting and negotiating of various license agreements as well as on general strategies for commercialization of IP.

Christopher has been practicing law since 2008 and joined Schjødt in 2022. His previous experience includes work at other law firms as well as a junior judgeship at the Patent and Market Court. He is recognized as a leading Intellectual Property attorney and patent litigation star by numerous prestigious ranking institutes such as Managing IP, Legal 500, IAM Patent 1000 and WTR 1000.

Christopher is a registered representative authorized to represent clients before the Unified Patent Court (UPC)

Christopher is the appointed expert on AIPPI’s international Standing Committee on Patents.

Practice Areas

• Dispute Resolution,
• Litigation & Arbitration
• Digital Innovation & TMT
• Intellectual Property
• Life Sciences
• Media & Entertainment
• Mining & Minerals
• Trade & Industry

Rankings

2022
“Christopher Tehrani is a humble genius and an excellent IP litigator, and specialised in international cases” – Legal 500,

2022
“Tehrani is an exceptional patent litigator whose impeccable skillset seamlessly crosses over into the trademark sphere.” WTR 1000

Education

2008
Masters of Law, Lund University

2003
Bachelor of Commerce, McGill University

Publications

2022
Legal 500 Patent Litigation Comparitive Guide

2022
Lexology Guide Trade Secrets

2022
Lexology Guide Licensing

2022
Wolters Kluwer White Paper: Preparing for the Unitary Patent

2020
BIO IP protection vs. public health interests